Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05332743 · ClinicalTrials.gov registry record · NA
Nutraceutical Supplement With Vegan Botanicals in Females With Self-Perceived Thinning Hair
A NA study of Hair Thinning, sponsored by Nutraceutical Wellness.
- Completed
- Registry status
- NA
- Development phase
- 110
- Enrollment target
- 2
- Study locations
NCT05332743: Completed NA study of Hair Thinning, sponsored by Nutraceutical Wellness.
NCT05332743 is a NA study of Hair Thinning that has completed, run by Nutraceutical Wellness. The registered enrollment target is 110 participants, above the 55-participant average among 10 other Hair Thinning trials with a reported enrollment target (100% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05332743, a NA study of Hair Thinning, has completed, sponsored by Nutraceutical Wellness.
- COMPLETED
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of the study is to evaluate the safety and efficacy of a vegan nutraceutical supplement with standardized botanicals in females leading a more plant-based lifestyle with self-perceived thinning hair
Primary Outcome
Terminal Hair Counts
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Nutrafol Vegan Women's Hair Supplement
Study Locations (2)
California
- Ablon Skin Institute and Research Center - Manhattan Beach
- Integrative Skin Science and Research - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2022-05-19 |
| Est. Completion | 2023-06-23 |
| Phase | NA |
What the finished NCT05332743 record still lists
NCT05332743 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, above the 55-participant average among 10 other Hair Thinning trials with a reported enrollment target (100% higher).
The record links to 1 condition, with Hair Thinning appearing as the primary indexed condition, and to 1 intervention - of which Nutrafol Vegan Women's Hair Supplement is the first listed.
NCT05332743 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05332743 about?
NCT05332743 is a clinical study titled "Nutraceutical Supplement With Vegan Botanicals in Females With Self-Perceived Thinning Hair". The purpose of the study is to evaluate the safety and efficacy of a vegan nutraceutical supplement with standardized botanicals in females leading a more plant-based lifestyle with self-perceived thinning hair
What is the current status of trial NCT05332743?
This trial is currently completed. It is a NA study. The enrollment target is 110 participants. The study started on 2022-05-19. Estimated completion is 2023-06-23.
What conditions does trial NCT05332743 study?
This clinical trial studies the following conditions: Hair Thinning.
What interventions are being tested in trial NCT05332743?
The interventions under investigation include: Nutrafol Vegan Women's Hair Supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05332743?
This trial is sponsored by Nutraceutical Wellness, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05332743 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hair Thinning
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05332743's enrollment target sits among peer trials
110 1st of 10 higher than 10 of 10 other Hair Thinning trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hair Thinning trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Combined Use of Supplement and Serum in Promoting Hair Growth in Women With Self-perceived Thinning Hair
RECRUITING · NA
-
A Clinical Trial to Examine the Efficacy of a Dietary Supplement to Improve the Health and Appearance of Hair.
ACTIVE NOT RECRUITING · NA
-
A Clinical Trial to Examine the Efficacy of a Supplement to Support Healthy Hair and Skin
ACTIVE NOT RECRUITING · NA
-
Efficacy and Safety of TargetCool + Benev Exosomes in Patients With Hair Thinning
ACTIVE NOT RECRUITING · NA
-
The Effects of an Oral Hair Supplement on Hair Density, Growth, and Microbiome
ACTIVE NOT RECRUITING · NA
-
Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI